Home Cart Sign in  
Chemical Structure| 405169-16-6 Chemical Structure| 405169-16-6

Structure of Dovitinib
CAS No.: 405169-16-6

Chemical Structure| 405169-16-6

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Dovitinib is a multitargeted RTK inhibitor, mostly for class III (FLT3/c-Kit) with IC50 of 1 nM/2 nM, also potent to class IV (FGFR1/3) and class V (VEGFR1-4) RTKs with IC50 of 8-13 nM.

Synonyms: CHIR-258; TKI258

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Dovitinib

CAS No. :405169-16-6
Formula : C21H21FN6O
M.W : 392.43
SMILES Code : CN1CCN(CC1)C2=CC3=C(N=C(N3)C4=C(C5=C(NC4=O)C=CC=C5F)N)C=C2
Synonyms :
CHIR-258; TKI258
MDL No. :MFCD10565680
InChI Key :PIQCTGMSNWUMAF-UHFFFAOYSA-N
Pubchem ID :135398510

Safety of Dovitinib

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Dovitinib

RTK

Isoform Comparison

Biological Activity

Target
  • VEGFR1

    VEGFR1/FLT1, IC50:10 nM

  • VEGFR3

    VEGFR3/FLT4, IC50:8 nM

  • VEGFR2

    VEGFR2/Flk1, IC50:13 nM

  • PDGFRβ

    PDGFRβ, IC50:27 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
YTN16 cells 1.0μM Dovitinib significantly inhibited phosphorylation of FGFR1 and PDGFRB in YTN16 cells, and repressed the expression of EMT markers Vimentin, SNAI1, SNAI2, and ZEB1, while inducing E-cadherin expression. PMC10592091
HGC-27 cells 1.0μM Dovitinib significantly inhibited phosphorylation of FGFR1 and PDGFRB in HGC-27 cells, and repressed the expression of EMT markers Vimentin, SNAI1, SNAI2, and ZEB1, while inducing E-cadherin expression. PMC10592091
HCT-116 3.05 μM 72 hours To evaluate the inhibitory effect of Dovitinib and Oxaliplatin combination on cell proliferation, the results showed that the combination treatment exhibited higher cytotoxicity in all cell lines PMC3996163
HT-29 5.21 μM 72 hours To evaluate the inhibitory effect of Dovitinib and Oxaliplatin combination on cell proliferation, the results showed that the combination treatment exhibited higher cytotoxicity in all cell lines PMC3996163
SW-480 4.33 μM 72 hours To evaluate the inhibitory effect of Dovitinib and Oxaliplatin combination on cell proliferation, the results showed that the combination treatment exhibited higher cytotoxicity in all cell lines PMC3996163
CaCO2 3.23 μM 72 hours To evaluate the inhibitory effect of Dovitinib and Oxaliplatin combination on cell proliferation, the results showed that the combination treatment exhibited higher cytotoxicity in all cell lines PMC3996163
LS174T 4.33 μM 72 hours To evaluate the inhibitory effect of Dovitinib and Oxaliplatin combination on cell proliferation, the results showed that the combination treatment exhibited higher cytotoxicity in all cell lines PMC3996163

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
mice syngeneic tumor model derived from YTN16 cells oral 1 μg Three times a week for 3 weeks Dovitinib significantly delayed tumor growth in YTN16-derived tumors, increased CD8+ T cell infiltration, and repressed the expression of EMT markers. PMC10592091
nude mice HT-29 human colorectal cancer xenograft model oral Dovitinib, intravenous Oxaliplatin 150 mg/kg D-luciferin or 7.5 mg/kg CycLuc1 To evaluate the inhibitory effect of Dovitinib and Oxaliplatin combination on tumor growth, the results showed that the combination treatment significantly inhibited tumor growth without showing apparent toxicity PMC3996163
mice MDA PCa 118b bone tumor model oral 60 mg/kg Dovitinib, 6.7 mg/kg Oxaliplatin Dovitinib every two days, Oxaliplatin once a week for 3 weeks Dovitinib significantly reduced tumor volume (assessed by MRI) and improved bone quality in tumor-bearing bones. PMC4407499
Mice Renal cell carcinoma tumorgraft model Oral gavage 40 or 60 mg/kg body weight daily for 3 weeks Dovitinib profoundly suppressed the growth of renal cell carcinoma tumorgrafts and was more effective than sunitinib and sirolimus. PMC3570965
Nude mice Cholangiocarcinoma patient derived xenograft (PDX) mouse model Oral gavage 25 mg/kg single injection, sacrificed after 12 hours To evaluate the inhibitory effect of Dovitinib on the growth of LIV31 xenograft tumors. The results showed that Dovitinib significantly inhibited tumor growth and was most effective in inhibiting vascular proliferation. PMC5119950

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT00279773 Acute Myeloid Leukemia PHASE1 TERMINATED - The University of Texas, M.D. ... More >>Anderson Cancer Center, Houston, Texas, 77020, United States Less <<
NCT01972750 First or Second Recurrence of ... More >>Glioblastoma Less << PHASE1 UNKNOWN 2025-11-16 Department of Neurology and Ce... More >>nter of Integrated Oncology, University Hospital Bonn, Bonn, 53105, Germany Less <<
NCT00303251 Melanoma PHASE1|PHASE2 COMPLETED - James Graham Brown Cancer Cent... More >>er, Louisville, Kentucky, 40202, United States|University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, 15232, United States|MD Anderson Cancer, Houston, Texas, 77030, United States Less <<
NCT00790426 Urothelial Cancer PHASE2 COMPLETED 2025-04-12 University of California San D... More >>iego - Moores Cancer Center UCSD, La Jolla, California, 92093-0658, United States|USC/Kenneth Norris Comprehensive Cancer Center Regulatory Contact 3, Los Angeles, California, 90053, United States|University Chicago Hospital CTKI258A2201, Chicago, Illinois, 60637, United States|Dana Farber Cancer Institute Dana 1230, Boston, Massachusetts, 02215, United States|Nevada Cancer Institute Nevada Cancer Institute, Las Vegas, Nevada, 89135, United States|Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering (2), New York, New York, 10065, United States|Duke University Medical Center Dept.ofDukeUniversityMedCtr(2), Durham, North Carolina, 27710, United States|The West Clinic, Memphis, Tennessee, 38120, United States|Novartis Investigative Site, Vienna, 1100, Austria|Novartis Investigative Site, Victoria, British Columbia, V8R 6V5, Canada|Novartis Investigative Site, Toronto, Ontario, M5G 2M9, Canada|Novartis Investigative Site, Berlin, 10098, Germany|Novartis Investigative Site, Dresden, 01307, Germany|Novartis Investigative Site, Ulm, 89081, Germany|Novartis Investigative Site, Roma, RM, 00152, Italy|Novartis Investigative Site, Sevilla, Andalucia, 41013, Spain|Novartis Investigative Site, Barcelona, Catalunya, 08003, Spain|Novartis Investigative Site, Barcelona, Catalunya, 08035, Spain|Novartis Investigative Site, Barcelona, 08041, Spain|Novartis Investigative Site, Madrid, 28034, Spain|Novartis Investigative Site, Madrid, 28041, Spain|Novartis Investigative Site, Madrid, 28050, Spain|Novartis Investigative Site, Tainan 704, Taiwan ROC, Taiwan|Novartis Investigative Site, Taipei, 10048, Taiwan|Novartis Investigative Site, Leeds, West Yorkshire, LS9 7TF, United Kingdom|Novartis Investigative Site, Southampton, SO16 6YD, United Kingdom Less <<
NCT00669097 Advanced Solid Malignancies PHASE1 COMPLETED - Novartis Investigative Site, A... More >>msterdam, Netherlands Less <<
NCT01791387 Clear Cell Renal Cell Carcinom... More >>a Less << PHASE2 UNKNOWN 2025-06-15 Auckland Hospital, Auckland, 1... More >>142, New Zealand Less <<
NCT01732107 Bladder Cancer PHASE2 TERMINATED 2017-03-06 Indiana University Melvin and ... More >>Bren Simon Cancer Center, Indianapolis, Indiana, 46202, United States|Johns Hopkins University: Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, 21231, United States|Fox Chase Cancer Center Extramural Research Program, Rockledge, Pennsylvania, 19046, United States Less <<
NCT01678105 Recurrent Adenoid Cystic Carci... More >>noma of the Salivary Glands|Metastatic Adenoid Cystic Carcinoma of the Salivary Glands|Salivary Gland Cancers|ACC Less << PHASE2 COMPLETED 2025-09-15 Tom Baker Cancer Centre, Calga... More >>ry, Ontario, T2N 4N2, Canada|Juravinski Cancer Centre, Hamilton, Ontario, L8V 5C2, Canada|London Health Sciences Centre, London, Ontario, N6A 4L6, Canada|Ottawa Hospital Regional Cancer Centre, Ottawa, Ontario, K1H 8L6, Canada Less <<
NCT01741116 Hormone Refractory Prostate Ca... More >>ncer Less << PHASE2 COMPLETED 2025-10-16 Korean Cancer Study Group, Seo... More >>ul, Chongro-ku, 110999, Korea, Republic of|Korea University Anam Hospital, Seoul, Seongbuk-gu, Inchon-ro, 136-705, Korea, Republic of Less <<
NCT01058434 Relapsed or Refractory Multipl... More >>e Myeloma Less << PHASE2 COMPLETED 2025-02-13 University of South Alabama / ... More >>Mitchell Cancer Institute Dept. of Mitchell Cancer Inst., Mobile, Alabama, 36688, United States|Central Hematology Oncology Medical Group, Alhambra, California, 91801, United States|Central Coast Medical Oncology Corporation, Santa Maria, California, 93454, United States|St. Jude Heritage Medical Group Virginia Crosson Cancer Center, Yorba Linda, California, 92886, United States|Kootenai Medical Center Kootenai Medical Center, Coeur d'Alene, Idaho, 83814, United States|Hematology and Oncology Specialists Dept of Hem&Onc Specialist - 2, Metairie, Louisiana, 70006, United States|Mayo Clinic - Rochester Rochester, Rochester, Minnesota, 55905, United States|Memorial Sloan Kettering Cancer Center MSKCC, New York, New York, 10021, United States|Duke University Medical Center Dept. of DUMC (4), Durham, North Carolina, 27710, United States|Lancaster Cancer Center, Lancaster, Pennsylvania, 17601, United States|Cancer Centers of the Carolinas Dept. of CC of the Carolinas, Greenville, South Carolina, 29605, United States|University of Tennessee Cancer Institute SC-2, Memphis, Tennessee, 38104, United States|University of Texas Southwestern Medical Center UTSW Medical Center, Dallas, Texas, 75390-8527, United States|University of Wisconsin SC, Madison, Wisconsin, 53792, United States|Medical College of Wisconsin Med College of Wisconsin, Milwaukee, Wisconsin, 53226, United States|Novartis Investigative Site, Adelaide, South Australia, 5000, Australia|Novartis Investigative Site, Melbourne, Victoria, 3002, Australia|Novartis Investigative Site, Prahran, Victoria, 3181, Australia|Novartis Investigative Site, Toronto, Ontario, M5G 2M9, Canada|Novartis Investigative Site, Montreal, Quebec, H3A 1A1, Canada|Novartis Investigative Site, Nantes Cedex 1, 44093, France|Novartis Investigative Site, Bochum, 44892, Germany|Novartis Investigative Site, Heidelberg, 69120, Germany|Novartis Investigative Site, K?ln, 50924, Germany|Novartis Investigative Site, Amsterdam, 1081 HV, Netherlands|Novartis Investigative Site, Rotterdam, 3015 CE, Netherlands|Novartis Investigative Site, Rotterdam, 3075 EA, Netherlands|Novartis Investigative Site, Altunizade, 34662, Turkey|Novartis Investigative Site, Ankara, 06100, Turkey|Novartis Investigative Site, Izmir, 35040, Turkey Less <<
NCT01576380 Adenocarcinoma, Scirrhous|Lini... More >>tis Plastica|Stomach Neoplasms|Stomach Diseases|Neoplasms by Site|Neoplasms Less << PHASE2 COMPLETED 2025-09-13 Novartis Investigative Site, N... More >>agoya, Aichi, 464-8681, Japan|Novartis Investigative Site, Kashiwa, Chiba, 277-8577, Japan|Novartis Investigative Site, Matsuyama, Ehime, 791-0280, Japan|Novartis Investigative Site, Sapporo-city, Hokkaido, 060-8648, Japan|Novartis Investigative Site, Takatsuki, Osaka, 569-8686, Japan|Novartis Investigative Site, Sunto-gun, Shizuoka, 411-8777, Japan|Novartis Investigative Site, Chuo-ku, Tokyo, 104-0045, Japan|Novartis Investigative Site, Koto, Tokyo, 135-8550, Japan Less <<
NCT01514526 Adrenocortical Carcinoma PHASE2 COMPLETED 2025-11-16 Complejo Hospitalario Universi... More >>tario de Santiago, Santiago de Compostela, A Coru?a, 15706, Spain|Hospital Universitario Fundación de Alcorcón, Alcorcón, Madrid, 28922, Spain|Hospital del Mar, Barcelona, 08003, Spain|Hospital Universitario Reina Sofía, Córdoba, 14004, Spain|Hospital Universitario Central de Asturias, Oviedo, 33006, Spain|Complejo Hospitalario de Navarra, Pamplona, 31008, Spain|Fundación Instituto Valenciano de Oncología, Valencia, 46009, Spain Less <<
NCT01471548 Advanced Solid Tumors PHASE1 COMPLETED 2025-05-12 Novartis Investigative Site, T... More >>akatsuki, Osaka, 569-8686, Japan|Novartis Investigative Site, Hidaka, Saitama, 350-1241, Japan Less <<
NCT01379534 Solid Tumors and Advanced Endo... More >>metrial Cancer|Endometrial Cancer|Second-line Treatment|VEGF Less << PHASE2 COMPLETED 2025-03-14 University of South Alabama / ... More >>Mitchell Cancer Institute Univ South Alabama, Mobile, Alabama, 36688, United States|St. Jude Heritage Medical Group St Jude, Fullerton, California, 92835, United States|USC/Kenneth Norris Comprehensive Cancer Center USC 2, Los Angeles, California, 90033, United States|Cedars Sinai Medical Center TKI258A2211 (SC), Los Angeles, California, 90048, United States|University of California at Los Angeles UCLA 3, Los Angeles, California, 90095, United States|Rocky Mountain Cancer Centers Dept. of Rocky Mountain Cancer, Greenwood Village, Colorado, United States|Florida Hospital Cancer Institute FL Hosp, Orlando, Florida, 32804, United States|Indiana University Health Goshen Center for Cancer IU Simon Cancer, Indianapolis, Indiana, 46202, United States|University of Iowa Hospitals & Clinics SC, Iowa City, Iowa, 52242, United States|Dana Farber Cancer Institute SC, Boston, Massachusetts, 02115, United States|Southeast Nebraska Oncology Cancer Center, Lincoln, Nebraska, 68510, United States|Hope A Woman's Cancer Center, Asheville, North Carolina, 28806, United States|Duke University Medical Center Duke3, Durham, North Carolina, 27710, United States|Community Oncology Research Network, Chattanooga, Tennessee, 37403, United States|The West Clinic SC, Memphis, Tennessee, 38120, United States|Texas Oncology, P.A. Austin, Bedford, Texas, 76022, United States|Texas Oncology, P.A. Tex Onc (3), Bedford, Texas, 76022, United States|Texas Oncology, P.A. SC, Fort Worth, Texas, 76104, United States|South Texas Oncology and Hematology, PA South Tex Onc, San Antonio, Texas, 78258, United States|Virginia Oncology Associates VOA - Lake Wright, *see Various Departments*, Virginia, United States|Cancer Care Northwest SC, Spokane, Washington, 99202, United States|Novartis Investigative Site, Belo Horizonte, MG, 30150-270, Brazil|Novartis Investigative Site, Porto Alegre, RS, 90610-000, Brazil|Novartis Investigative Site, Ribeirao Preto, SP, 14048-900, Brazil|Novartis Investigative Site, Genova, GE, 16132, Italy|Novartis Investigative Site, Monza, MB, 20900, Italy|Novartis Investigative Site, Milano, MI, 20133, Italy|Novartis Investigative Site, Milano, MI, 20141, Italy|Novartis Investigative Site, Pisa, PI, 56126, Italy|Novartis Investigative Site, Roma, RM, 00168, Italy|Novartis Investigative Site, Candiolo, TO, 10060, Italy|Novartis Investigative Site, Seoul, Korea, 135-710, Korea, Republic of|Novartis Investigative Site, Seoul, 738-736, Korea, Republic of|Novartis Investigative Site, Grafton, Auckland, New Zealand|Novartis Investigative Site, Cordoba, Andalucia, 14004, Spain|Novartis Investigative Site, Málaga, Andalucia, 29010, Spain|Novartis Investigative Site, Oviedo, Asturias, 33006, Spain|Novartis Investigative Site, Sabadell, Barcelona, 08208, Spain|Novartis Investigative Site, Barcelona, Catalunya, 08035, Spain|Novartis Investigative Site, Majadahonda, Madrid, 28222, Spain|Novartis Investigative Site, Murcia, 30008, Spain|Novartis Investigative Site, Glasgow, G12 0YN, United Kingdom|Novartis Investigative Site, Leeds, LS9 7TF, United Kingdom|Novartis Investigative Site, London, NW1 2BU, United Kingdom|Novartis Investigative Site, Nottingham, NG5 1PB, United Kingdom Less <<
NCT01443481 Solid Tumors|Hepatic Impairmen... More >>t Less << PHASE1 COMPLETED 2025-10-14 University of California at Lo... More >>s Angeles Dept. of UCLA (4), Los Angeles, California, 90095, United States|Duke University Medical Center DUMC, Durham, North Carolina, 27710, United States|Cancer Therapy & Research Center / UT Health Science Center SC, San Antonio, Texas, 78229, United States|Novartis Investigative Site, Gent, 9000, Belgium|Novartis Investigative Site, Frankfurt, 60590, Germany|Novartis Investigative Site, Hannover, 30625, Germany|Novartis Investigative Site, Milano, MI, 20133, Italy|Novartis Investigative Site, Rozzano, MI, 20089, Italy|Novartis Investigative Site, Verona, VR, 37126, Italy|Novartis Investigative Site, Amsterdam, 1066 CX, Netherlands|Novartis Investigative Site, Maastricht, 5800, Netherlands|Novartis Investigative Site, Singapore, 119228, Singapore Less <<
NCT01861197 Squamous NSCLC PHASE2 UNKNOWN - Samsung Medical Center, Seoul,... More >> 135-710, Korea, Republic of Less <<
NCT01964144 Thyroid Cancer PHASE2 COMPLETED 2025-10-14 Division of Medical Oncology, ... More >>Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, 120-752, Korea, Republic of Less <<
NCT00715182 Advanced/ Metastatic Renal Cel... More >>l Cancer Less << PHASE1 COMPLETED 2025-07-12 Novartis Investigative Site, S... More >>an Francisco, California, United States|Novartis Investigative Site, Durham, North Carolina, 27710, United States|Novartis Investigative Site, Seattle, Washington, 98109-1023, United States|Novartis Investigative Site, Bordeaux Cedex, 33075, France|Novartis Investigative Site, Villejuif Cedex, 94805, France|Novartis Investigative Site, Hannover, 30625, Germany|Novartis Investigative Site, München, 81675, Germany|Novartis Investigative Site, Rotterdam, 3075 EA, Netherlands|Novartis Investigative Site, Madrid, 28041, Spain|Novartis Investigative Site, Taipei, Taiwan, ROC, 112, Taiwan|Novartis Investigative Site, Taichung, 40705, Taiwan|Novartis Investigative Site, Taipei, 10002, Taiwan Less <<
NCT01635907 Advanced Metastatic Paragangli... More >>oma|Advanced Metastatic Pheochromocytoma|Recurrent Paraganglioma|Recurrent Pheochromocytoma|Unresectable Paraganglioma|Unresectable Pheochromocytoma Less << PHASE2 COMPLETED 2016-04-11 Abramson Cancer Center of the ... More >>University of Pennsylvania, Philadelphia, Pennsylvania, 19104, United States Less <<
NCT01262027 Breast Cancer PHASE2 COMPLETED 2015-11-25 University of Texas MD Anderso... More >>n Cancer Center, Houston, Texas, 77030, United States Less <<
NCT00958971 Metastatic Breast Cancer PHASE2 COMPLETED 2025-03-11 Comprehensive Blood and Cancer... More >> Center Dept CBCC (3), Bakersfield, California, 93309, United States|Tower Cancer Research, Beverly Hills, California, 90211, United States|UCLA/ University of California Los Angeles Div. of Hematology/Oncology, Los Angeles, California, 90095, United States|Cancer Care Associates Medical Group Dept. of CCA, Redondo Beach, California, 90277, United States|Central Coast Medical Oncology Corporation, Santa Maria, California, 93454, United States|Florida Cancer Specialists Dept.of FloridaCancerSpec. (2), Fort Myers, Florida, 33901, United States|Kansas City Cancer Center KCCC (3), Overland Park, Kansas, 66210, United States|Associates in Oncology/Hematology, P.C., Rockville, Maryland, 20850, United States|Comprehensive Cancer Centers of Nevada, Henderson, Nevada, 89052, United States|UNC/ Lineberger Comprehensive Cancer Center Dept. of Linberger Cancer Ctr, Chapel Hill, North Carolina, 27599-7295, United States|Northwest Cancer Specialists Northwest Office (2), Portland, Oregon, 97210, United States|Texas Oncology, P.A. Dept. of Texas Oncology, Bedford, Texas, 76022, United States|Texas Oncology, P.A. Austin, Dallas, Texas, 75246, United States|Texas Oncology, P.A. Presbyterian Hospital, Dallas, Texas, 75246, United States|Texas Oncology, P.A. Texas Oncology - Sammons, Dallas, Texas, 75246, United States|Tyler Cancer Center Dept.ofTylerCancerCtr. (2), Tyler, Texas, 75702, United States|Fairfax Northern Virginia Hematology Oncology Fairfax NVH, Fairfax, Virginia, 22031, United States|Blue Ridge Research Center at Roanoke Neurological Center Blue Ridge Cancer Care, Roanoke, Virginia, 24014, United States|Novartis Investigative Site, Edmonton, Alberta, T6G 1Z2, Canada|Novartis Investigative Site, Montreal, Quebec, H2W 1T8, Canada|Novartis Investigative Site, Helsinki, FIN-00029, Finland|Novartis Investigative Site, Lyon Cedex, 69373, France|Novartis Investigative Site, Saint-Herblain Cédex, 44805, France|Novartis Investigative Site, Toulouse Cedex 3, 31052, France|Novartis Investigative Site, Villejuif Cedex, 94805, France|Novartis Investigative Site, Cuneo, CN, 12100, Italy|Novartis Investigative Site, Cremona, CR, 26100, Italy|Novartis Investigative Site, Parma, PR, 43100, Italy|Novartis Investigative Site, Candiolo, TO, 10060, Italy|Novartis Investigative Site, Napoli, 80131, Italy|Novartis Investigative Site, Negrar, 37024, Italy|Novartis Investigative Site, Barcelona, Catalu?a, 08035, Spain|Novartis Investigative Site, Lleida, Catalu?a, 25198, Spain|Novartis Investigative Site, Madrid, 28041, Spain|Novartis Investigative Site, Taipei, 10048, Taiwan|Novartis Investigative Site, Glasgow, G12 0YN, United Kingdom|Novartis Investigative Site, London, SE1 9RT, United Kingdom|Novartis Investigative Site, London, SW3 6JJ, United Kingdom Less <<
NCT00243763 Multiple Myeloma PHASE1 TERMINATED - Mayo Clinic - Arizona, Scottsd... More >>ale, Arizona, 85259, United States|H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, 33612, United States|Emory University, Atlanta, Georgia, 30322, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, 02115, United States|Mayo Clinic - Minnesota, Rochester, Minnesota, 55905, United States Less <<
NCT01266070 Von Hippel-Lindau Syndrome PHASE2 TERMINATED 2025-12-15 University of Texas MD Anderso... More >>n Cancer Center, Houston, Texas, 77030, United States Less <<
NCT01421004 Advanced Solid Tumors|Excludin... More >>g Breast Cancer Less << PHASE1 COMPLETED 2025-07-14 City of Hope National Medical ... More >>Center SC-2, Duarte, California, 91010-3000, United States|University of California at Los Angeles UCLA LeConte Location, Los Angeles, California, 90095, United States|University of California San Francisco UCSF (SC), San Francisco, California, 94101, United States|Florida Cancer Specialists Sarasota Office, Fort Myers, Florida, 33901, United States|Rush University Medical Center Rush 3, Chicago, Illinois, 60612, United States|Washington University School of Medicine SC, Saint Louis, Missouri, 63110, United States|Montefiore Medical Center Montefiore Medical Center (SC), Bronx, New York, 10467, United States|University of Oklahoma Health Sciences Center OUHSC - SC, Oklahoma City, Oklahoma, 73104, United States|University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, 15232-1305, United States|Sarah Cannon Research Institute Sarah Cannon Research (SC), Nashville, Tennessee, 37203, United States|Sammons Cancer Center - Texas Oncology SC-2, Dallas, Texas, 78246, United States|Cancer Therapy & Research Center / UT Health Science Center InstituteForDrugDevelopment(5), San Antonio, Texas, 78229, United States|University of Utah / Huntsman Cancer Institute Huntsman, Salt Lake City, Utah, 84112, United States|University of Wisconsin Univ Wisc, Madison, Wisconsin, 53792, United States Less <<
NCT01676714 Non-Small Cell Lung Cancer|Col... More >>orectal Cancer Less << PHASE2 COMPLETED 2025-06-16 University of California Compr... More >>ehensive Cancer Center, Sacramento, California, 95817, United States Less <<
NCT01769547 Advanced Malignant Pleural Mes... More >>othelioma|MPM Less << PHASE2 TERMINATED 2025-06-15 Tom Baker Cancer Centre, Calga... More >>ry, Alberta, T2N 4N2, Canada|Juravinski Cancer Centre, Hamilton, Ontario, L8V 5C2, Canada|Ottawa General Hospital Cancer Centre, Ottawa, Ontario, K1H 8L6, Canada|Northeast Cancer Centre, Health Sciences North, Sudbury, Ontario, P3E 5J1, Canada|Princess Margaret Hospital, Toronto, Ontario, M5G 1X6, Canada Less <<
NCT01888965 Colorectal Cancer|Pancreas Can... More >>cer Less << PHASE2 TERMINATED 2025-10-14 Georgetown University- Lombard... More >>i Cancer Center, Washington, District of Columbia, 20007, United States Less <<
NCT01155713 Neoplasm|Cancer|Tumors PHASE1 COMPLETED 2025-11-13 Scottsdale Healthcare/TGen Cli... More >>nical Research Service TGen Clinical Research Service, Scottsdale, Arizona, 85258, United States|Duke University Medical Center, Durham, North Carolina, 27710, United States|Sarah Cannon Research Institute Sarah Cannon Research Instit, Nashville, Tennessee, 37203, United States|University of Utah / Huntsman Cancer Institute, Salt Lake City, Utah, 84112, United States Less <<
NCT01719549 Gastric Cancer PHASE2 COMPLETED 2025-11-16 Asan Medical Center, Seoul, 13... More >>8-736, Korea, Republic of Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.55mL

0.51mL

0.25mL

12.74mL

2.55mL

1.27mL

25.48mL

5.10mL

2.55mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

[1]Huynh H, Chow PK, et al. Dovitinib demonstrates antitumor and antimetastatic activities in xenograft models of hepatocellular carcinoma. J Hepatol. 2012 Mar;56(3):595-601.

[2]Huynh H, Chow PK, et al. Dovitinib demonstrates antitumor and antimetastatic activities in xenograft models of hepatocellular carcinoma. J Hepatol. 2012 Mar;56(3):595-601.

[3]Lee SH, Lopes de Menezes D, Vora J, Harris A, Ye H, Nordahl L, Garrett E, Samara E, Aukerman SL, Gelb AB, Heise C. In vivo target modulation and biological activity of CHIR-258, a multitargeted growth factor receptor kinase inhibitor, in colon cancer models. Clin Cancer Res. 2005 May 15;11(10):3633-41. doi: 10.1158/1078-0432.CCR-04-2129. PMID: 15897558.

[4]Trudel S, Li ZH, Wei E, Wiesmann M, Chang H, Chen C, Reece D, Heise C, Stewart AK. CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma. Blood. 2005 Apr 1;105(7):2941-8.

[5]Eucker J, Zang C, Zhou Y, Li X, Habbel P, Schulz CO, Scholz C, Liu H. TKI258, a multi-tyrosine kinase inhibitor is efficacious against human infant/childhood lymphoblastic leukemia in vitro. Anticancer Res. 2014 Sep;34(9):4899-907.

[6]Kelly LM, Yu JC, Boulton CL, Apatira M, Li J, Sullivan CM, Williams I, Amaral SM, Curley DP, Duclos N, Neuberg D, Scarborough RM, Pandey A, Hollenbach S, Abe K, Lokker NA, Gilliland DG, Giese NA. CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML). Cancer Cell. 2002 Jun;1(5):421-32. doi: 10.1016/s1535-6108(02)00070-3. PMID: 12124172.

[7]Griswold IJ, Shen LJ, La Rosée P, Demehri S, Heinrich MC, Braziel RM, McGreevey L, Haley AD, Giese N, Druker BJ, Deininger MW. Effects of MLN518, a dual FLT3 and KIT inhibitor, on normal and malignant hematopoiesis. Blood. 2004 Nov 1;104(9):2912-8. doi: 10.1182/blood-2003-05-1669. Epub 2004 Jul 8. PMID: 15242881.

 

Historical Records

Categories